| Document |
Document Title |
|
WO/2022/200580A1 |
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.The co...
|
|
WO/2022/200786A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, includ...
|
|
WO/2022/200787A1 |
There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2022/200785A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, i...
|
|
WO/2022/204099A1 |
The present invention provides a compound of Formula I: (I) wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Form...
|
|
WO/2022/200463A1 |
This disclosure relates to a combination therapy for treating subjects having a fibrotic disorder. More particularly, the disclosure relates to combination therapies comprising an AXL inhibitor (AXLi) and a renin-angiotensin system inhib...
|
|
WO/2022/201161A1 |
Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatic...
|
|
WO/2022/196816A1 |
Provided are a colicin-fighting monoclonal antibody molecule or a derivative thereof, and a pharmaceutical composition containing the same, for ameliorating acute lung injury and acute worsening of pulmonary fibrosis. The pharmaceutica...
|
|
WO/2022/198192A1 |
The present disclosure provides methods for treating lupus nephritis in an individual that is greater than or equal to 12 years of age and less than 18 years of age. In some embodiments, the methods comprise administering to the individu...
|
|
WO/2022/196683A1 |
Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. A serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxi...
|
|
WO/2022/197641A1 |
The present invention relates to 1H-pyrazolo[3,4-d]pyrimidin-6-yl- amine derivatives of formula (I) as hematopoietic progenitor kinase 1 (HPK1) modulators and/or inhibitors for the treatment of cancer and other diseases, such as e.g. vir...
|
|
WO/2022/188762A1 |
A pharmaceutical composition for treating or alleviating a hangover from alcohol, which comprises radix codonopsis pilosulae, poria, and pericarpium citri reticulatae, or further comprises rhizoma zingiberis and rhizoma atractylodis macr...
|
|
WO/2022/189010A1 |
Described herein are compositions and methods of alleviating, preventing, reducing, suppressing, and/or treating a bacterial infection in a human or non-human animal. The compositions and methods are useful in supporting, for example, ge...
|
|
WO/2022/191194A1 |
One of the problems addressed by the present invention is the provision of an agent for inhibiting renal damage induced by rhabdomyolysis. The present invention uses cilastatin or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/192545A1 |
Provided herein are alpha V beta 6 and alpha V beta 1 integrin inhibitors, methods of making such alpha V beta 6 and alpha V beta 1 integrin inhibitors, pharmaceutical compositions of alpha V beta 6 and alpha V beta 1 integrin inhibitors...
|
|
WO/2022/191193A1 |
One of the problems of the present invention is to provide an agent for preventing a kidney injury induced by a hemolytic reaction. In the present invention, cilastatin or a pharmaceutically acceptable salt thereof is used.
|
|
WO/2022/184755A1 |
The present invention relates to Galectin-3 inhibitors of Formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds, and their medical uses.
|
|
WO/2022/186813A1 |
Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat d...
|
|
WO/2022/184000A1 |
A novel imidazole compound serving as a TGF-β inhibitor, and in particular a TGFβR-1 inhibitor, a pharmaceutical composition comprising the compound, and a use of the compound and the composition in the prevention and/or treatment of T...
|
|
WO/2022/187419A1 |
The present disclosure provides compounds of Formula (I): and the salts or solvates thereof, wherein A1, B1, L, and X2 are as defined in the specification. The present disclosure also relates to uses of the compounds, e.g., asandrogen re...
|
|
WO/2022/187142A1 |
Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a drug (e.g., a first drug) that is vadadustat (i.e., {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}ac...
|
|
WO/2022/182547A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
WO/2022/181532A1 |
Provided is a method for inhibiting the function of myostatin. Provided are: an antisense oligonucleotide having a base length of 15-30 and a base sequence complementary to the target sequence of exon 3 of myostatin gene, the antisense o...
|
|
WO/2022/182574A1 |
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or ...
|
|
WO/2022/178594A1 |
The present disclosure relates to functionalized amino compounds that can provide inhibitors of C-reactive protein (CRP). The present disclosure also relates to pharmaceutical compositions containing such compounds, methods for using suc...
|
|
WO/2022/180274A1 |
The present invention relates to oxybutynin for use in the treatment of a medical condition, wherein oxybutynin is administered to the subject in need of treatment by means of a vaginal ring, that comprises a drug reservoir for the liqui...
|
|
WO/2022/182753A1 |
The present invention provides methods of reducing, inhibiting, preventing and treating vascular diseases. More specifically, the present disclosure provides methods of treating vascular diseases with the modulator of p66Shc signaling SH...
|
|
WO/2022/181797A1 |
The present disclosure provides a therapy for diabetes that targets abnormal stem cells by using an HDAC inhibitor combined with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabet...
|
|
WO/2022/176970A1 |
Provided is an anti-PAD4 antibody in which HCDR1 includes an amino acid sequence of SEQ ID NO: 1, HCDR2 includes an amino acid sequence of SEQ ID NO: 2, HCDR3 includes an amino acid sequence of SEQ ID NO: 3, LCDR1 includes an amino acid ...
|
|
WO/2022/175514A1 |
The present invention covers substituted N-(pyridin-2-yl)-acetamide compounds of general formula (I): (I) wherein X, Y, R1, R2, R3, R4, and R5 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and co...
|
|
WO/2022/178146A1 |
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of NLRP3 RNA in a cell or subject, and in certain instances reducing the amount of NLRP3 protein in a cell or subject. These compounds, ...
|
|
WO/2022/176917A1 |
Provided are: a non-human animal or a part of the same in which the function of Mipep gene is totally or partially lost in adipose tissues or the expression level of Mipep gene in adipose tissues is lowered compared to a wild type; and m...
|
|
WO/2022/178020A1 |
Disclosed herein are vaccine compositions for the treatment and prevention of urinary tract infections (UT!s) and methods for delivery of the vaccine compositions. Moreover, the disclosure provides adjuvant compositions for vaccines to m...
|
|
WO/2022/172072A1 |
The present invention is related to a composition comprising bioactive molecules having beneficial effects on senescence of adult renal stem cells, in particular comprising: decenoic acid, nonanoic acid, valproic acid and heparin.
|
|
WO/2022/171525A1 |
The present invention relates to danegaptide, or a pharmaceutically acceptable salt thereof for use in the treatment of a kidney disease, such as a chronic kidney disease, for example Diabetic Nephropathy and/or Chronic Kidney Disease.
|
|
WO/2022/168808A1 |
The present invention pertains to: a compound that is represented by formula (I), that has a mPGES-1 inhibitory effect, and that is useful as an active ingredient of a medicine for treating and/or preventing diseases such as inflammation...
|
|
WO/2022/166817A1 |
Disclosed are a heterocyclic compound, and an intermediate thereof, a preparation method therefor and the use thereof. Namely, provided are a heterocyclic compound as shown in formula I-a, and a tautomer and a pharmaceutically acceptable...
|
|
WO/2022/166560A1 |
The present invention relates to a pharmaceutical composition comprising an azo calixarene supramolecular compound of formula (I) as a targeting pharmaceutical excipient for hypoxia responses and new use of the azo calixarene supramolecu...
|
|
WO/2022/167778A1 |
Ebselen, 2-Phenyl-1,2-benzisoselenazol-3(2H)-one, (I) is a modulator of the adenosine A2A receptor and is indicated for use in the treatment or prevention of a disease or condition mediated by the adenosine A2A receptor.
|
|
WO/2022/166369A1 |
Disclosed is a crystal form A of a compound. The compound is S-(-)-2,3-methylenedioxy-5,8,13,13a-tetrahydro-10,11-dimetho
xy-6H- dibenzo[a,g]quinolizine, and the X-ray powder diffraction pattern of the crystal form A comprises three or m...
|
|
WO/2022/169855A1 |
The present invention includes compositions and methods for preventing or treating a patient for kidney injury comprising administering an effective amount of a compound of Formula I: where n = 0-5; X = NH, O, S, or CH2; Y = phenyl, or a...
|
|
WO/2022/166548A1 |
Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a ...
|
|
WO/2022/169279A1 |
Kidney organ-derived stem cells or organoids according to the present disclosure: are easy to apply to a therapeutic procedure; can be supplied in a large amount due to the high self-proliferation rate thereof; have a high potential to d...
|
|
WO/2022/165092A1 |
The present disclosure provides biomarkers and methods that are useful in treating, screening, and/or evaluating treatment of fibrotic diseases with methyl (Z)-3-(((4-(N-methyl-2- (4-methylpiperazin-l-yl)acetamido)phenyl)amino)(phenyl)me...
|
|
WO/2022/161416A1 |
Disclosed are an aromatic compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopic compound thereof. The compound has high P2X4 antagonistic activity, good safety, and good pharmacoki...
|
|
WO/2022/161274A1 |
Disclosed in the present invention are a pyrimidine-2,4-diamine compound, a preparation method therefor and the use thereof, relating to the technical field of pharmaceutical chemistry. The pyrimidine-2,4-diamine compound of the present ...
|
|
WO/2022/165263A1 |
Provided herein are methods and compositions for treating, managing, and protecting against bacterial infection of urinary tract tissue in individuals suffering or susceptible to urinary tract tissue infection. The methods and compositio...
|
|
WO/2022/164997A1 |
Provided herein are methods and corresponding compounds for treating fibrotic disease by administering to a subject a compound of Formula I or pharmaceutically acceptable salt thereof, which inhibits phosphorylation of Smad2/3, according...
|
|
WO/2022/161510A1 |
Disclosed is a use of canagliflozin in the preparation of a drug for treating a nodular sclerosis-mediated disease. Canagliflozin is capable of selectively targeting TSC mutant cells, significantly affecting the activity of TSC mutant ce...
|
